Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Birociclib with Clarithromycin or Rifampicin in Healthy Subjects
NCT04951713Phase 1Unknown
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Jul 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of birociclib in breast cancer (2 arms), sponsored by Xuanzhu Biopharmaceutical. Primary endpoint: Primary PK Endpoints at Day 22. Status: unknown.
02
Drugs
birociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04951713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04951713.